At NegotiumBio, we support global pharma and biotech companies to develop and implement their outsourcing strategy across any drug modality. Our team is experienced in completing complex business transactions across a wide diversity of drug modalities including cellular and gene therapies (CAR-T, TCR, CRISPR, viral vector, autologous / allogenic supply chains, stem cell), biologics (mAB, protein, etc.), and small molecules. We help you to qualify, choose and manage your suppliers applying a systematic diligence process. This allows you to mitigate the risks commonly associated with outsourced manufacturing, regardless of your location. In addition, we provide guidance for developing raw material (GMP and non-GMP) management programs through either direct OEM or consolidation strategies enabled with the latest digital cataloging and/or marketplace cloud tools. RESEARCH: We scan the market to help you to make informed outsourcing decisions. MODELLING: We infer the costs to manufacture your product through our deep understanding of technical operations and the materials markets. RISK ASSESSMENT: We evaluate your supply chain holistically to identify both macro and micro risks. DUE DILIGENCE: We help you ensure a well-documented and thorough supplier qualification process to meet cGMP requirements. NEGOTIATE: We work with your scientists and development teams to better position them at the negotiation table MANAGE: We are happy to continue to manage the supplier relationship and support your subsequent project management needs. CONTACT US: NegotiumBio, LLC, North Andover, USA NegotiumBio GmbH, Basel, Switzerland inquiries@negotiumbio.com